Study S000470

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT06640972
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 68
Start: 2024-09-27
Primary completion: 2025-01-04
Lead sponsor: Response Pharmaceuticals
Conditions: Triglycerides; Weight Gain Trajectory; Cholesterol, Elevated
Interventions: DRUG:RDX-002; DRUG:Placebo
Results posted: TRUE

Registered primary outcomes

Incremental Postprandial Triglycerides (TG) [12 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.